

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM657058

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Exela Holdings, Inc.		06/25/2021	Corporation: DELAWARE
Exela Pharma Sciences, LLC		06/25/2021	Limited Liability Company: DELAWARE
Exela Pharmsci, Inc.		06/25/2021	Corporation: VIRGINIA
Exela Sterile Products LLC		06/25/2021	Limited Liability Company: NORTH CAROLINA
Exela Sterile Equipment, LLC		06/25/2021	Limited Liability Company: NORTH CAROLINA
Exela Advanced Strategies LLC		06/25/2021	Limited Liability Company: NORTH CAROLINA
Agelex, LLC		06/25/2021	Limited Liability Company: DELAWARE
Exela Health Systems, LLC		06/25/2021	Limited Liability Company: NORTH CAROLINA
Exela Initiatives, LLC		06/25/2021	Limited Liability Company: NORTH CAROLINA
Exela Innovations, LLC		06/25/2021	Limited Liability Company: NORTH CAROLINA
Exela Sterile Medicines LLC		06/25/2021	Limited Liability Company: DELAWARE

RECEIVING PARTY DATA

Name:	Live Oak Banking Company
Street Address:	1740 Tiburon Drive
City:	Wilmington
State/Country:	NORTH CAROLINA
Postal Code:	28403
Entity Type:	Corporation: NORTH CAROLINA

PROPERTY NUMBERS Total: 13

Property Type	Number	Word Mark
Registration Number:	4739675	EXELA
Registration Number:	4477973	EXELA
Registration Number:	4685756	EXELA

OP \$340.00 4739675

Property Type	Number	Word Mark
Serial Number:	87177104	EXELA
Serial Number:	87900729	CYSALO
Serial Number:	88230298	ELCIS
Serial Number:	88350906	ELCYS
Serial Number:	88895942	CALSTRYN
Registration Number:	6036892	GLYRX-PF
Registration Number:	4433582	BLOXIVERZ
Registration Number:	4704141	VAZCULEP
Registration Number:	5055498	AKOVAZ
Serial Number:	90464068	MUZREL

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2023704750
Email: ipteam@coagencyglobal.com
Correspondent Name: Jennifer Tindie
Address Line 1: 1025 Connecticut Ave., NW, Suite 712
Address Line 2: COGENY GLOBAL INC.
Address Line 4: Washington, D.C. 20036

ATTORNEY DOCKET NUMBER:	1413235 TM Exela Pharma
NAME OF SUBMITTER:	Kerri DeRuyter
SIGNATURE:	/Kerri DeRuyter/
DATE SIGNED:	06/30/2021

Total Attachments: 15

- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page1.tif
- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page2.tif
- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page3.tif
- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page4.tif
- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page5.tif
- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page6.tif
- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page7.tif
- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page8.tif
- source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement (executed)#page9.tif

source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement
(executed)#page10.tif

source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement
(executed)#page11.tif

source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement
(executed)#page12.tif

source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement
(executed)#page13.tif

source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement
(executed)#page14.tif

source=LOB-Exela Pharma Sciences - Patents, Trademarks & Copyrights Security Agreement
(executed)#page15.tif

PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT

This Patent, Trademark and Copyright Security Agreement (the “**Agreement**”), dated as of June 25, 2021, is entered into by and among **EACH OF THE PERSONS LISTED ON THE SIGNATURE PAGES HERETO AND EACH OF THE OTHER PERSONS WHICH BECOME PLEDGORS HEREUNDER FROM TIME TO TIME** (each a “**Pledgor**” and collectively, the “**Pledgors**”) and **LIVE OAK BANKING COMPANY**, as lender (the “**Lender**”).

WHEREAS, pursuant to that certain Credit Agreement, dated as of even date herewith dated as of the date hereof, among **EXELA PHARMA SCIENCES, LLC**, a Delaware limited liability company (the “**Borrower**”), **EXELA HOLDINGS, INC.**, a Delaware corporation (“**Holdings**”) and the Lender (as amended, restated, modified or supplemented from time to time, the “**Credit Agreement**”), the Lender has agreed to provide certain loans and other financial accommodations to the Borrower, and each Pledgor has agreed, among other things, to grant a security interest to the Lender in certain patents, trademarks, copyrights and other property as security for such loans and other obligations as more fully described herein.

NOW, THEREFORE, intending to be legally bound hereby, the parties hereto agree as follows:

1. Defined Terms.

(a) Except as otherwise expressly provided herein, (i) capitalized terms used in this Agreement shall have the respective meanings assigned to them in the Credit Agreement and (ii) the rules of construction set forth in Section 1.03 of the Credit Agreement shall apply to this Agreement. Where applicable and except as otherwise expressly provided herein, terms used herein (whether or not capitalized) shall have the respective meanings assigned to them in the Uniform Commercial Code as enacted in the State of North Carolina as amended from time to time (the “**Code**”).

(b) “**Patents, Trademarks and Copyrights**” shall mean and include all of each Pledgor’s present and future right, title and interest in and to all Intellectual Property (as such term is defined in the Security Agreement), including, without limitation, the following: all trade names, patent applications, patents, trademark applications (excluding any “intent to use” trademark applications for which a statement of use has not been filed with the U.S. Patent and Trademark Office), trademarks and copyrights, whether now owned or hereafter acquired by any Pledgor, including, without limitation, those listed on Schedule A hereto, including all proceeds thereof (such as, by way of example, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof, and the goodwill of the business to which any of the patents, trademarks and copyrights relate.

(c) “**Secured Obligations**” shall mean and include the Obligations, as defined in the Credit Agreement.

2. To secure the full payment and performance of all Secured Obligations, each Pledgor grants and conveys a security interest to the Lender and its affiliates, in the entire right, title and interest of such Pledgor in and to all of its Patents, Trademarks and Copyrights. The security interests granted pursuant to this Agreement are granted in conjunction with the security interests granted to the Lender pursuant to that certain Security Agreement, dated as of even date, among the Borrower and the Lender (the “**Security Agreement**”). Pledgor hereby acknowledges and affirms that the rights and remedies of the

Lender with respect to the security interest in the Patents, Trademarks and Copyrights made and granted hereby are in conjunction with and more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

3. Each Pledgor jointly and severally represents and warrants, and covenants that:

(a) the Patents, Trademarks and Copyrights are subsisting and have not been adjudged invalid or unenforceable, in whole or in part;

(b) to such Pledgor's knowledge, each of the Patents, Trademarks and Copyrights that is material to the Pledgor's business is valid and enforceable;

(c) to such Pledgor's knowledge, such Pledgor is the sole and exclusive owner of the entire and unencumbered right, title and interest in and to each of the Patents, Trademarks and Copyrights that is material to the Pledgor's business, free and clear of any liens, charges and encumbrances, except for Permitted Liens and non-exclusive licenses granted in the ordinary course of business, including pledges, assignments, shop rights and covenants by such Pledgor not to sue third persons;

(d) such Pledgor has the corporate, limited liability company or partnership power and authority, as applicable, to enter into this Agreement and perform its terms;

(e) no claim has been made in writing to such Pledgor or, to the knowledge of such Pledgor, any other person that the use of any of the Patents, Trademarks and Copyrights does or may violate the rights of any third party;

(f) such Pledgor has used, and will continue to use for the duration of this Agreement, consistent standards of quality in its manufacture of products sold under the Patents, Trademarks and Copyrights; and

(g) such Pledgor has used, and will continue to use for the duration of this Agreement, proper statutory notice in connection with its use of the Patents, Trademarks and Copyrights, except for those Patents, Trademarks and Copyrights that are hereafter allowed to lapse in accordance with Section 11 hereof.

4. Each of the obligations and additional liabilities of each and every Pledgor under this Agreement are joint and several with the obligations of the other Pledgors, and each Pledgor hereby waives to the fullest extent permitted by Law any defense it may otherwise have to the payment and performance of the Obligations that its liability hereunder is limited and not joint and several. Each Pledgor acknowledges and agrees that the foregoing waiver serves as a material inducement to the agreement of the Lender to make the Loans, and that the Lender is relying on such waiver in entering into this Agreement. The undertakings of each Pledgor hereunder secure the obligations of the Borrower, itself and the other Pledgors. The Lender may, in its sole discretion, elect to enforce this Agreement against any Pledgor without any duty or responsibility to pursue any other Pledgor and such an election by the Lender shall not be a defense to any action the Lender may elect to take against any Pledgor. The Lender hereby reserves all rights against each Pledgor.

5. Each Pledgor agrees that, until indefeasible repayment in full of all of the Secured Obligations, it will not enter into any agreement (for example, a license agreement) which is inconsistent with such Pledgor's obligations under this Agreement, the Security Agreement or the Credit Agreement, without the Lender's prior written consent which shall not be unreasonably withheld, except such Pledgor may

license the Patents, Trademarks and Copyrights and technology (i) in the ordinary course of business without the Lender's consent to suppliers and customers to facilitate the manufacture and use of such Pledgor's products and (ii) in the event any such Patents, Trademarks and Copyrights or technology is no longer used or useful in the business of the Pledgors and upon not less than 15 days' prior written notice to the Lender, in connection with the resolution of any third party claim relating to any of the Patents, Trademarks and Copyrights.

6. If, before indefeasible repayment in full of all of the Secured Obligations, any Pledgor shall own any new trademarks or any new copyrightable or patentable inventions, or any patent application or patent for any reissue, division, continuation, renewal, extension, or continuation in part of any Patent, Trademark or Copyright or any improvement on any Patent, Trademark or Copyright, the provisions of this Agreement shall automatically apply thereto and such Pledgor shall give to the Lender prompt notice thereof in writing. Each Pledgor and the Lender agree to modify this Agreement by amending Schedule A to include any future patents, patent applications, trademark applications, trademarks, copyrights or copyright applications and the provisions of this Agreement shall apply thereto.

7. Lender shall have, in addition to all other rights and remedies given it by this Agreement and those rights and remedies set forth in the Security Agreement and the Credit Agreement, those allowed by applicable Law and the rights and remedies of a secured party under the Uniform Commercial Code as enacted in any jurisdiction in which the Patents, Trademarks and Copyrights may be located and, without limiting the generality of the foregoing, if an Event of Default has occurred and is continuing, Lender may immediately, without demand of performance and without other notice (except as set forth below) or demand whatsoever to any Pledgor, all of which are hereby expressly waived, and without advertisement, sell at public or private sale or otherwise realize upon, in a city that the Lender shall designate by notice to such Pledgor, in Wilmington, North Carolina or elsewhere, the whole or from time to time any part of the Patents, Trademarks and Copyrights, or any interest which such Pledgor may have therein and shall apply such proceeds in accordance with the terms of the Credit Agreement. Notice of any sale or other disposition of the Patents, Trademarks and Copyrights shall be given to Pledgors at least ten (10) days before the time of any intended public or private sale or other disposition of the Patents, Trademarks and Copyrights is to be made, which each Pledgor hereby agrees shall be reasonable notice of such sale or other disposition. At any such sale or other disposition, Lender may, to the extent permissible under applicable Law, purchase the whole or any part of the Patents, Trademarks and Copyrights sold, free from any right of redemption on the part of any Pledgor, which right is hereby waived and released.

8. If any Event of Default shall have occurred and be continuing, each Pledgor hereby authorizes and empowers the Lender to make, constitute and appoint any officer or agent of the Lender, as the Lender may select in its exclusive discretion, as such Pledgor's true and lawful attorney-in-fact, with the power to endorse such Pledgor's name on all applications, documents, papers and instruments necessary for the Lender to use the Patents, Trademarks and Copyrights, or to grant or issue, on commercially reasonable terms, any exclusive or nonexclusive license under the Patents, Trademarks and Copyrights to any third person, or necessary for the Lender to assign, pledge, convey or otherwise transfer title in or dispose, on commercially reasonable terms, of the Patents, Trademarks and Copyrights to any third Person. Each Pledgor hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney, being coupled with an interest, shall be irrevocable for the life of this Agreement.

9. Upon indefeasible repayment in full of all of the Secured Obligations, this Agreement shall terminate and the Lender shall execute and deliver to each Pledgor all deeds, assignments and other instruments as may be necessary or proper to re-vest in such Pledgor full title to the Patents, Trademarks

and Copyrights, subject to any disposition thereof which may have been made by the Lender pursuant hereto.

10. Any and all reasonable and documented out-of-pocket fees, costs and expenses, of whatever kind or nature, including reasonable attorneys' fees and expenses incurred by the Lender in connection with the preparation of this Agreement and all other documents relating hereto and the consummation of this transaction, the filing or recording of any documents (including all taxes in connection therewith) in public offices, the payment or discharge of any taxes, counsel fees, maintenance fees, encumbrances, the protection, maintenance or preservation of the Patents, Trademarks and Copyrights, or the defense or prosecution of any actions or proceedings arising out of or related to the Patents, Trademarks and Copyrights, shall be borne and paid by the Pledgors in accordance with the terms of the Credit Agreement.

11. Except as otherwise determined in the reasonable business judgment by any Pledgor, each Pledgor shall have the duty to take reasonable steps to prosecute diligently any patent applications of the Patents, Trademarks and Copyrights pending as of the date of this Agreement or thereafter that are material to the business of such Pledgor until indefeasible repayment in full of the Secured Obligations, and to preserve and maintain all rights in patent applications and patents of the Patents, including the payment of all maintenance fees, except as determined in the reasonable business judgment of any Pledgor and as permitted under the Credit Agreement. Any reasonable and documented out-of-pocket expenses incurred in connection with such an application shall be borne by the Pledgors. No Pledgor shall abandon any Patent, Trademark or Copyright, except in a transaction as may be permitted under the Credit Agreement.

12. Each Pledgor shall have the right to bring suit, action or other proceeding in its own name, and, with the consent of the Lender, which shall not be unreasonably withheld, to join the Lender, if necessary, as a party to such suit so long as the Lender is satisfied that such joinder will not subject it to any risk of liability, to enforce the Patents, Trademarks and Copyrights and any licenses thereunder. Each Pledgor shall promptly, upon demand, reimburse and indemnify the Lender for all damages (other than indirect, special, consequential or punitive damages), reasonable and documented out-of-pocket costs and expenses, including reasonable legal fees, incurred by the Lender as a result of such suit or joinder by such Pledgor.

13. No course of dealing between any Pledgor and the Lender, nor any failure to exercise nor any delay in exercising, on the part of the Lender, any right, remedy, power or privilege of the Lender hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. No waiver of a single Event of Default shall be deemed a waiver of a subsequent Event of Default. All of the Lender's rights and remedies with respect to the Patents, Trademarks and Copyrights, whether established hereby or by the Credit Agreement, the Security Agreement or by any other agreements or by Law, shall be cumulative and not exclusive of any rights or remedies which it may otherwise have under the other Loan Documents or by Law, and the Lender may enforce any one or more remedies hereunder successively or concurrently at its option.

14. It is the intention of the parties that this Agreement be enforceable to the fullest extent permissible under applicable Law, but that the unenforceability (or modification to conform to such Law) of any provision or provisions hereof shall not render unenforceable, or impair, the remainder hereof. If any provision in this Agreement shall be held invalid or unenforceable in whole or in part in any jurisdiction, this Agreement shall, as to such jurisdiction, be deemed amended to modify or delete, as necessary, the offending provision or provisions and to alter the bounds thereof in order to render it or

them valid and enforceable to the maximum extent permitted by applicable Law, without in any manner affecting the validity or enforceability of such provision or provisions in any other jurisdiction or the remaining provisions hereof in any jurisdiction without invalidating the remaining provisions hereof.

15. This Agreement, in conjunction with the Security Agreement, supersedes all prior understandings and agreements, whether written or oral, between the parties hereto relating to a grant of a security interest in the Patents, Trademarks and Copyrights by any Pledgor. This Agreement is subject to waiver, modification, supplement or amendment only by a writing signed by the parties, except as provided in Section 6 and Section 22 hereof with respect to additions and supplements to Schedule A hereto.

16. The benefits and burdens of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties; provided, however, that no Pledgor may assign or transfer any of its rights or obligations hereunder or any interest herein, and any such purported assignment or transfer shall be null and void.

17. This Agreement shall be governed by, construed, and enforced in accordance with the internal laws of the State of North Carolina, without regard to its conflict of laws principles, except to the extent the validity or perfection of the security interests or the remedies hereunder in respect of any Patents, Trademarks or Copyrights are governed by the law of a jurisdiction other than the State of North Carolina.

18. This Agreement may be executed by different parties hereto on any number of separate counterparts, each of which, when so executed and delivered, shall be deemed an original, and all such counterparts shall together constitute one and the same instrument. Each Pledgor acknowledges and agrees that a telecopy or electronic transmission to the Lender of the signature page hereof purporting to be signed on behalf of such Pledgor shall constitute effective and binding execution and delivery hereof by such Pledgor.

19. EACH PLEDGOR HEREBY IRREVOCABLY WAIVES TRIAL BY JURY IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM OF ANY KIND ARISING OUT OF OR RELATED TO THIS AGREEMENT, THE CREDIT AGREEMENT, ANY OTHER LOAN DOCUMENT OR THE PATENTS, TRADEMARKS AND COPYRIGHTS TO THE FULLEST EXTENT PERMITTED BY LAW.

20. Each Pledgor acknowledges and agrees that, in addition to the other rights of the Lender hereunder and under the other Loan Documents, because the Lender's remedies at law for failure of such Pledgor to comply with the provisions hereof relating to the Lender's rights (i) to inspect the books and records related to the Patents, Trademarks and Copyrights, (ii) to receive the various notifications such Pledgor is required to deliver hereunder, (iii) to obtain copies of agreements and documents as provided herein with respect to the Patents, Trademarks and Copyrights, (iv) to enforce the provisions hereof pursuant to which such Pledgor has appointed the Lender its attorney-in-fact, and (v) to enforce the Lender's remedies hereunder, would be inadequate and that any such failure would not be adequately compensable in damages, such Pledgor agrees that each such provision hereof may be specifically enforced.

21. Each Pledgor hereby acknowledges, represents, and warrants that it receives synergistic benefits by virtue of its affiliation with the Borrower and/or the other Pledgors and that it will receive direct and indirect benefits from the financing arrangements contemplated by the Credit Agreement and that such benefits, together with the rights of contribution and subrogation that may arise in connection herewith are a reasonably equivalent exchange of value in return for providing this Agreement.


22. At any time after the initial execution and delivery of this Agreement to the Lender, additional Persons may become parties to this Agreement and thereby acquire the duties and rights of being Pledgors hereunder by executing and delivering to the Lender a joinder agreement pursuant to the Credit Agreement and, in addition, a new Schedule A hereto shall be provided to the Lender with respect to such new Pledgor. No notice of the addition of any Pledgor shall be required to be given to any pre-existing Pledgor and each Pledgor hereby consents thereto.

[SIGNATURES APPEAR ON FOLLOWING PAGES]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers or agents thereunto duly authorized, as of the date first above written.

PLEDGORS:


EXELA PHARMA SCIENCES, LLC

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President


EXELA HOLDINGS, INC.

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President


EXELA PHARMSCI, INC.

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President


EXELA ADVANCED STRATEGIES LLC

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President

EXELA HEALTH SYSTEMS, LLC


By:  (SEAL)
Name: Phanesh B. Koneru
Title: President

EXELA INNOVATIONS, LLC


By:  (SEAL)
Name: Phanesh B. Koneru
Title: Manager

[SIGNATURES CONTINUE ON THE FOLLOWING PAGE]


AGELEX, LLC

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President


EXELA INITIATIVES, LLC

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President

EXELA STERILE EQUIPMENT, LLC

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President

EXELA STERILE PRODUCTS LLC

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President

EXELA STERILE MEDICINES LLC

By:  (SEAL)
Name: Phanesh B. Koneru
Title: President

[SIGNATURES CONTINUE ON THE FOLLOWING PAGE]

LENDER:

LIVE OAK BANKING COMPANY

By: Cynthia R. Bridger
Name: Cynthia R. Bridger
Title: AVP – Closing

**SCHEDULE A
TO
PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT**

**LIST OF REGISTERED PATENTS, TRADEMARKS,
TRADE NAMES AND COPYRIGHTS**

1. Registered Patents:

PATENTS						
<u>Owner</u>	<u>Title</u>	<u>Application / Registration No.</u>	<u>Inventor</u>	<u>Country</u>	<u>Filing Date</u>	<u>Status</u>
Exela Holdings, Inc.	PHYTONADIONE COMPOSITIONS AND RELATED METHODS	16/043,582	Phanesh Koneru, Sreerarama Murthy Mallipeddi, Jonathan E. Sterling	United States	July 24, 2018	Allowed
Exela Holdings, Inc.	PHYTONADIONE COMPOSITIONS AND RELATED METHODS	16/043,830	Phanesh Koneru, Sreerarama Murthy Mallipeddi, Jonathan E. Sterling	United States	July 24, 2018	Allowed
Exela Holdings, Inc.	Phytonadione Compositions and Related Methods	10,028,921	Sree Rama Murthy Mallipeddi; Phanesh babu Koneru	United States	February 26, 2016	Issued
Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	10,478,453	John Maloney; Aruna Koganti; Phanesh Koneru	USA	11/19/2019	Issued
Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	10,583,155	John Maloney; Aruna Koganti; Phanesh Koneru	USA	10/28/2019	Issued

PATENTS

Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	10,653,719	John Maloney; Aruna Koganti; Phanesh Koneru	USA	5/19/2020	Issued
Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	10,905,713	John Maloney; Aruna Koganti; Phanesh Koneru	USA	4/16/2020	Issued
Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	10,905,714	John Maloney; Aruna Koganti; Phanesh Koneru	USA	4/16/2020	Issued
Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	10,912,795	John Maloney; Aruna Koganti; Phanesh Koneru	USA	4/16/2020	Issued
Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	10,918,662	John Maloney; Aruna Koganti; Phanesh Koneru	USA	4/16/2020	Issued
Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	10,933,089	John Maloney; Aruna Koganti; Phanesh Koneru	USA	1/17/2020	Issued
Exela Pharma Sciences, LLC	Stable, highly pure L-cysteine compositions for injection and methods of use	17/164,263	John Maloney; Aruna Koganti; Phanesh Koneru	USA	02/01/2021	Pending
Exela Pharma	Stable, highly pure L-cysteine compositions for	17/188,922	John Maloney; Aruna	USA	03/01/2021	Pending

PATENTS

Sciences, LLC	injection and methods of use		Koganti; Phanesh Koneru			
Exela Pharma Sciences, LLC	Phosphate Compositions with Low Aluminum Content	17/067,253	Phanesh Koneru; John Maloney; Aruna Koganti	USA	10/09/2020	Allowed
Exela Pharma Sciences, LLC	Ganciclovir Compositions and Related Methods	9,486,530	Sree Rama Murthy Mallipeddi; Phanesh babu Koneru; Jonathan E. Sterling	USA	9/2/2014	Issued
Exela Pharma Sciences, LLC	Nitrofurantoin Parenteral Compositions	16/659,941	Sree Rama Murthy Mallipeddi; Phanesh babu Koneru	USA	10/21/2019	Pending
Exela Pharma Sciences, LLC	Methocarbamol Compositions and Related Methods	16/953,010	Sree Rama Murthy Mallipeddi; Phanesh babu Koneru	USA	11/19/2020	Pending
Exela Pharma Sciences, LLC	Ganciclovir Compositions and Related Methods	16/817,570	Sree Rama Murthy Mallipeddi; Phanesh babu Koneru; John Downes Maloney	USA	3/12/2020	Pending

PATENTS						
Exela Pharma Sciences, LLC	Ganciclovir Compositions and Related Methods	16/814,871	Sree Rama Murthy Mallipeddi; Phanesh babu Koneru; John Downes Maloney	USA	3/10/2020	Pending
Exela PharmSci, Inc.	Compositions Comprising Oxygen-Sensitive Active Substances and Methods for Preparing Said Compositions	17/083,206	Phanesh B. Koneru; Sreerama Murthy Mallipeddi; Jonathan E. Sterling	USA	10/28/2020	Pending
Exela PharmSci, Inc.	Method and system for delivering substitute medical therapies with restricted access	7,885,827	Phanesh B. Koneru	USA	6/10/2010	Issued
Exela PharmSci, Inc.	Method and system for delivering medical therapies	7,885,824	Phanesh B. Koneru	USA	6/29/2006 (with priority to CIP filing on 12-09-2005 and provisional filing date 12-10-2004)	Issued
Exela PharmSci, Inc.	Method and system for delivering substitute medical therapies with restricted access	7,765,110	Phanesh B. Koneru	USA	6/29/2006	Issued
Exela Sterile Medicines	Cysteine Composition and Injection	10,493,051	Sutterer, et al	USA	3/15/2019	Issued
Exela Sterile Medicines	Cysteine Composition and Injection	10,543,186	Sutterer, et al	USA	4/2/2019	Issued
Exela Sterile Medicines	Cysteine Composition and Injection	11,045,483	Sutterer, et al	USA	10/21/2019	Issued
Exela Sterile Medicines	Cysteine Composition and Injection	10,702,490	Sutterer, et al	USA	11/7/2019	Issued

PATENTS						
Exela Sterile Medicines	Cysteine Compositions and Injection	16/658,873	Sutterer, et al	USA	10/21/2019	pending
Exela Sterile Medicines	Cysteine Compositions and Injection	16/722,436	Sutterer, et al	USA	10/20/2019	pending
Exela Sterile Medicines	Cysteine Compositions and Injection	17/139420	Sutterer, et al	USA	12/31/2020	pending

2. Trademarks

TRADEMARKS					
<u>Owner</u>	<u>Trademark</u>	<u>Registration/ Application No.</u>	<u>Country</u>	<u>Registration/ Application Date</u>	<u>Status</u>
Exela Holdings, Inc.	Exela	4739675	USA	5/19/2015	Registered
Exela Holdings, Inc.	Exela	4477973	USA	2/4/2014	Registered
Exela Holdings, Inc.	Exela (Stylized)	4685756	USA	2/10/2015	Registered
Exela Holdings, Inc.	Exela (Stylized)	87/177104	USA	9/20/2016	Pending
Exela Holdings, Inc.	CYSALO	87900729	USA	4/30/2018	Allowed. Statement of Use or First Extension of Time Due: September 19, 2019
Exela Holdings, Inc.	ELCIS	88230298	USA	12/14/2018	Allowed. Statement of Use Due or First Extension of Time Due: December 18, 2019
Exela Holdings, Inc.	ELCYS	88350906	USA	3/21/2019	Published
Exela Holdings, Inc.	CALSTRYN	88/895942	USA	4/30/2020	Pending
Exela Holdings, Inc.	GLYRX-PF	6036892	USA	4/21/2020	Registered
Exela Sterile Medicines, LLC	BLOXIVERZ	4433582	USA	11/12/2013	Registered

Exela Sterile Medicines, LLC	VAZCUL EP	4704141	USA	3/17/2015	Registered
Exela Sterile Medicines, LLC	AKOVAZ	5055498	USA	10/04/2016	Registered
Exela Holdings, Inc	MUZREL	90464068	USA	1/31/2021	Pending

3. Trade Names: None

4. Copyright: None